Merck Ordered to Pay $4.5 Million in Vioxx Case

Alberto Culver's board backs away from Sally Beauty-Regis merger; Target and CVS post results; plus more stocks in the news Thursday

Merck (MRK) the jury reportedly finds that Merck failed to warn Vioxx users of the drug's heart risks; the company was ordered to pay the plaintiff at least $4.5 million.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.